Web-Banner-for-LNC.jpg

New Drug Indications - February 2023


atezolizumab

Tecentriq

Pharmaceutical company:  Genentech

NEW INDICATION & DOSAGE

Unresectable or metastatic alveolar soft part sarcoma

Adults:  840-mg IV infusion every 2 weeks, or 1,200 mg every 3 weeks, or 1,680 mg every 4 weeks until disease progression or unacceptable toxicity occurs.

Children age 2 and older:  15-mg/kg IV infusion (up to a maximum of 1,200 mg) every 3 weeks until disease progression or unacceptable toxicity occurs.

Released: February 2023

Nursing Drug Handbook

© 2023 Wolters Kluwer


 

cariprazine

Vraylar

Pharmaceutical company:  AbbVie

NEW INDICATION & DOSAGE

Adjunctive therapy to antidepressants for the treatment of major depressive disorder

Adults:  Initially, 1.5 mg PO once daily. May increase to 3 mg once daily on day 15 based on patient’s response and tolerability. Maximum dosage is 3 mg daily.

Released: February 2023

Nursing Drug Handbook

© 2023 Wolters Kluwer


 

ibrexafungerp

Brexafemme

Pharmaceutical company:  Scynexis, Inc.

NEW INDICATION & DOSAGE

Reduction of incidence of recurrent vulvovaginal candidiasis

Adult and pediatric females who are postmenarchal:  300 mg (two 150 mg tablets) PO approximately 12 hours apart for 1 day for a total daily dosage of 600 mg monthly for 6 months.

Adjust-a-dose:  If concomitantly used with strong CYP3A inhibitor, give one 150 mg tablet approximately 12 hours apart for 1 day for a total daily dosage of 300 mg monthly for 6 months.

Released: February 2023

Nursing Drug Handbook

© 2023 Wolters Kluwer


 

tocilizumab

Actemra

Pharmaceutical company:  Genentech

NEW INDICATION & DOSAGE

Coronavirus disease 2019 in patients who are hospitalized, receiving systemic corticosteroids, and who require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation

Adults:  8 mg/kg IV infusion over 60 minutes. If clinical signs or symptoms worsen or don’t improve after the first dose, one additional dose may be given at least 8 hours after the initial infusion. Maximum recommended dosage is 800 mg/infusion.

Adjust-a-dose:  Don’t initiate in patients with an ANC below 1,000 per mm 3 , platelet count below 50,000 mm 3 , or ALT or AST above 10 times the upper limit of normal.

Released: February 2023

Nursing Drug Handbook

© 2023 Wolters Kluwer